INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/13/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/11/23
Initial Data from Allarity's Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer PatientsGlobeNewsWire • 07/05/23
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock SplitGlobeNewsWire • 06/27/23
Allarity Therapeutics Announces Adjournment of Special Meeting of StockholdersGlobeNewsWire • 06/20/23
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual MeetingGlobeNewsWire • 05/30/23
Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023Accesswire • 04/27/23
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public OfferingGlobeNewsWire • 04/19/23
This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' TrialAccesswire • 04/17/23
Abstract Evaluating Allarity's DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual MeetingGlobeNewsWire • 04/11/23
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical StudiesGlobeNewsWire • 03/28/23
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid TumorsGlobeNewsWire • 03/20/23
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersGlobeNewsWire • 01/20/23